Is Teladoc, Inc. (TDOC)’s Fuel Running Low? The Stock Reaches 52-Week High Today

June 13, 2018 - By Kurt Siggers

Teladoc, Inc. (NYSE:TDOC) Logo

The stock of Teladoc, Inc. (NYSE:TDOC) hit a new 52-week high and has $62.59 target or 6.00 % above today’s $59.05 share price. The 5 months bullish chart indicates low risk for the $3.76B company. The 1-year high was reported on Jun, 13 by Barchart.com. If the $62.59 price target is reached, the company will be worth $225.60M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 4.14% or $2.35 during the last trading session, reaching $59.05. About 2.28M shares traded or 138.11% up from the average. Teladoc, Inc. (NYSE:TDOC) has risen 66.23% since June 13, 2017 and is uptrending. It has outperformed by 53.66% the S&P500.

Analysts await Teladoc, Inc. (NYSE:TDOC) to report earnings on August, 1. They expect $-0.35 EPS, down 25.00 % or $0.07 from last year’s $-0.28 per share. After $-0.39 actual EPS reported by Teladoc, Inc. for the previous quarter, Wall Street now forecasts -10.26 % EPS growth.

Teladoc, Inc. (NYSE:TDOC) Ratings Coverage

Among 13 analysts covering Teladoc (NYSE:TDOC), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Teladoc had 23 analyst reports since January 8, 2018 according to SRatingsIntel. Robert W. Baird maintained the shares of TDOC in report on Tuesday, June 5 with “Neutral” rating. Canaccord Genuity maintained Teladoc, Inc. (NYSE:TDOC) rating on Wednesday, February 28. Canaccord Genuity has “Buy” rating and $45 target. Canaccord Genuity maintained the shares of TDOC in report on Friday, April 13 with “Buy” rating. Citigroup maintained Teladoc, Inc. (NYSE:TDOC) on Tuesday, June 5 with “Buy” rating. The firm has “Buy” rating by Craig Hallum given on Tuesday, June 5. The firm earned “Hold” rating on Monday, June 4 by Cantor Fitzgerald. As per Monday, June 4, the company rating was maintained by Oppenheimer. Canaccord Genuity maintained it with “Buy” rating and $4300 target in Tuesday, April 3 report. The rating was maintained by J.P. Morgan with “Buy” on Tuesday, May 8. The stock has “Buy” rating by KeyBanc Capital Markets on Monday, January 8.

More notable recent Teladoc, Inc. (NYSE:TDOC) news were published by: Fool.com which released: “Why Teladoc Inc. Stock Gained 18% in May” on June 07, 2018, also Globenewswire.com with their article: “Teladoc Acquires Global Virtual Care Provider, Advance Medical” published on June 04, 2018, Seekingalpha.com published: “Teladoc: Pump The Brakes” on June 13, 2018. More interesting news about Teladoc, Inc. (NYSE:TDOC) were released by: Seekingalpha.com and their article: “Teladoc Acquires Advance Medical For Global Service Expansion” published on June 07, 2018 as well as Seekingalpha.com‘s news article titled: “Teladoc, Inc. (TDOC) Teladoc Acquires Advance Medical (Transcript)” with publication date: June 05, 2018.

Teladoc, Inc. operates a telehealth platform that provides on-demand healthcare services to its members in the United States. The company has market cap of $3.76 billion. The Company’s solution connects clients with its physicians and behavioral health professionals that treat a range of conditions and cases, including acute diagnoses, such as upper respiratory infection, urinary tract infection, and sinusitis; dermatological conditions; anxiety; and smoking cessation. It currently has negative earnings. The firm offers its services through mobile devices, the Internet, video, and phone.

Teladoc, Inc. (NYSE:TDOC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: